Who
Brinkley Ruth Williams
Director
Company insider
Files Form 4 as: Director, Travere Therapeutics; Director, Natera; Director, Chattem.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $329K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 26 Jan 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —86 | filing |
| 24 Apr 2026filed 28 Apr 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —86 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —73 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —73 | filing |
| 31 Oct 2025filed 4 Nov 2025 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —97 | filing |
| 25 Jul 2025filed 29 Jul 2025 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —112 | filing |
| 27 Jun 2025filed 1 Jul 2025 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —2,143 | filing |
| 15 May 2025filed 16 May 2025 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —2,964 | filing |
| 8 May 2024filed 10 May 2024 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 8 May 2024filed 10 May 2024 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 27 Oct 2023filed 31 Oct 2023 | NTRA Nateraoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $13K515 at $25.03 | filing |
| 28 Jul 2023filed 1 Aug 2023 | NTRA Nateraoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $13K428 at $29.68 | filing |
| 17 May 2023filed 19 May 2023 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.